Joseph J. Ferra Jr - Dec 16, 2024 Form 4 Insider Report for Elevation Oncology, Inc. (ELEV)

Role
CHIEF EXECUTIVE OFFICER, Director
Signature
/s/ Robert Yang, Attorney-in-Fact
Stock symbol
ELEV
Transactions as of
Dec 16, 2024
Transactions value $
-$2,963
Form type
4
Date filed
12/18/2024, 04:15 PM
Previous filing
Sep 18, 2024
Next filing
Feb 19, 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ELEV Common Stock Options Exercise +12.6K +12.37% 114K Dec 16, 2024 Direct F1
transaction ELEV Common Stock Tax liability -$2.96K -4.63K -4.06% $0.64 109K Dec 16, 2024 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ELEV Restricted Stock Unit Options Exercise $0 -12.6K -33.34% $0.00 25.1K Dec 16, 2024 Common Stock 12.6K Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.
F2 25% of the RSUs vested on June 16, 2022, and the remainder will vest as to 1/16 of the total RSUs quarterly until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date.
F3 The RSUs do not expire; they either vest or are canceled prior to the vesting date.